Serum FGF-23 and Vitamin D Deficiency
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
We aimed to determine the effect of vitamin D replacement therapy on serum FGF-23 concentrations in vitamin D deficient women and to compare the FGF-23 concentrations of vitamin D deficient patients with healthy subjects and patients with genetically-determined hypophosphatemic rickets.
| Condition |
|---|
|
Osteomalacia |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Effects Of Vitamin D Replacement Therapy on Serum FGF-23 Concentrations in Vitamin D Deficient Women In Short Term |
| Groups/Cohorts |
|---|
|
Vitamin D deficient females
(n =18, mean age 29.1±9.9 yrs)
|
|
vitamin D sufficient healthy females
(control group; n = 19, mean age 28.5±5.2 yrs)
|
|
genetically-determined hypophosphatemic rahitis
(n=13, mean age 26.5±15.1 yrs)
|
Detailed Description:
Study group was composed of vitamin D deficient females (n =18, mean age 29.1±9.9 yrs), vitamin D sufficient healthy females (control group; n = 19, mean age 28.5±5.2 yrs) and patients with genetically-determined hypophosphatemic rickets (n=13, mean age 26.5±15.1 yrs). Groups were compared for serum FGF-23, 1,25 dihydroxy vitamin D3, calcium, phosphate, bone turnover markers, intact parathyroid hormone and urinary excretion of calcium and phosphate. Vitamin D deficient group was re-evaluated after a standard treatment regimen.
Eligibility| Ages Eligible for Study: | 9 Years to 44 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Group 1: Eighteen premenopausal female patients with a diagnosis of vitamin D deficient osteomalacia were included in this group. Vitamin D deficiency was diagnosed according to the serum 25 hydroxy vitamin D3 (25OHD) concentrations (< 30 ng/mL). Reasons for vitamin D deficiency were verified as insufficient exposure to sunlight, frequent parturition and prolonged lactation. All of these patients received a standard treatment regimen; oral Vitamin D3 150 000 IU once for all and subsequently 880 IU D3 and 1000 mg calcium carbonate for six weeks. This group was also evaluated after replacement therapy at sixth week.
Group 2: Nineteen healthy premenopausal women who had normal levels of serum 25OHD Vitamin (>30 ng/mL) composed the control group.
Group 3: Thirteen hypophosphatemic rickets (3 autosomal dominant and 10 X-linked; 9 female and 4 male) were included in this group.
Inclusion Criteria:
- Serum 25OHD Vitamin <30 ng/mL for group 1
- Serum 25OHD Vitamin >30 ng/mL for control group
Exclusion Criteria:
- Receiving medication(s) affecting bone metabolism
- History of gastrointestinal disease and malabsorption
- History of renal and liver disease
Contacts and Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT01102751 History of Changes |
| Other Study ID Numbers: | Istanbul University, Research Fund |
| Study First Received: | April 12, 2010 |
| Last Updated: | April 12, 2010 |
| Health Authority: | Turkey: Ethics Committee |
Keywords provided by Istanbul University:
|
fibroblast growth factor 23 Osteomalacia vitamin D |
Additional relevant MeSH terms:
|
Osteomalacia Vitamin D Deficiency Bone Diseases, Metabolic Bone Diseases Musculoskeletal Diseases Calcium Metabolism Disorders Metabolic Diseases Avitaminosis Deficiency Diseases Malnutrition |
Nutrition Disorders Vitamin D Ergocalciferols Vitamins Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on May 22, 2013